Answers are grounded in this paper and cite their sources.
Despite major advances in the treatment of cancer, resistance to multiple chemotherapeutic agents remains a major cause of treatment failure. Some tumors are initially resistant to many of the most active antineoplastic agents. Other tumors that are initially sensitive to cytotoxic agents often recur and fre- quently develop resistance to a broad range ofchemotherapeutic agents including those used during the initial therapy. Both the intrinsic and acquired resistance to chemotherapeutic agents have been inherently difficult to study in the clinical setting. However, drug-resistant cell lines have provided a tool for studying the mechanisms underlying resistance to the drugs used in chemotherapy. Although drug-resistant cell lines are usually derived by selection for resistance to a single cyto- toxic agent, they often develop cross-resistance to a broad spectrum of structurally and functionally unrelated com- pounds. This phenomenon has been termed multidrug resis- tance. Recently, an understanding of the biological basis of multidrug resistance has begun to emerge through the applica- tion of molecular genetics. This approach has led to the iden- tification, isolation, and characterization of a gene family whose members include genes with the capacity to confer multidrug resistance on otherwise drug-sensitive cells. Molecu- lar probes and antibodies developed as a consequence of genetic analysis promise a new and precise level of understand- ing of the role of this gene family in human physiology and tumor biology. This knowledge will in turn be crucial for the development of strategies for circumventing multidrug resis- tance in the clinical setting.
No takes yet. Share an insight, caveat, or question.
Croop et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: